Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 565

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

Open access
Tirode, Franck, Surdez, Didier, Ma, Xiaotu, Parker, Matthew, Le Deley, Marie Cécile, Bahrami, Armita, Zhang, Zhaojie, Lapouble, Eve, Grossetête-Lalami, Sandrine, Rusch, Michael, Reynaud, Stéphanie, Rio-Frio, Thomas, Hedlund, Erin, Wu, Gang, Chen, Xiang, Pierron, Gaelle, Oberlin, Odile, Zaidi, Sakina, Lemmon, Gordon, Gupta, Pankaj, Vadodaria, Bhavin, Easton, John, Gut, Marta, Ding, Li, Mardis, Elaine R., Wilson, Richard K., Shurtleff, Sheila, Laurence, Valérie, Michon, Jean, Marec-Bérard, Perrine, Gut, Ivo, Downing, James, Dyer, Michael, Zhang, Jinghui, Delattre, Olivier·2014·Cancer Discovery

Abstract

Ewing sarcoma is a primary bone tumor initiated by EWSR1–ETS gene fusions. To identify secondary genetic lesions that contribute to tumor progression, we performed whole-genome sequencing of 112 Ewing sarcoma samples and matched germline DNA. Overall, Ewing sarcoma tumors had relatively few single-nucleotide variants, indels, structural variants, and copy-number alterations. Apart from whole chromosome arm copy-number changes, the most common somatic mutations were detected in STAG2 (17%), CDKN2A (12%), TP53 (7%), EZH2, BCOR, and ZMYM3 (2.7% each). Strikingly, STAG2 mutations and CDKN2A deletions were mutually exclusive, as confirmed in Ewing sarcoma cell lines. In an expanded cohort of 299 patients with clinical data, we discovered that STAG2 and TP53 mutations are often concurrent and are associated with poor outcome. Finally, we detected subclonal STAG2 mutations in diagnostic tumors and expansion of STAG2-immunonegative cells in relapsed tumors as compared with matched diagnostic samples. Significance: Whole-genome sequencing reveals that the somatic mutation rate in Ewing sarcoma is low. Tumors that harbor STAG2 and TP53 mutations have a particularly dismal prognosis with current treatments and require alternative therapies. Novel drugs that target epigenetic regulators may constitute viable therapeutic strategies in a subset of patients with mutations in chromatin modifiers. Cancer Discov; 4(11); 1342–53. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 1243

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0622

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 565

Metadata

Authors
Tirode, F., Surdez, D., Ma, X., Parker, M., Le Deley, M. C., Bahrami, A., Zhang, Z., Lapouble, E., Grossetête-Lalami, S., Rusch, M., Reynaud, S., Rio-Frio, T., Hedlund, E., Wu, G., Chen, X., Pierron, G., Oberlin, O., Zaidi, S., Lemmon, G., Gupta, P., Vadodaria, B., Easton, J., Gut, M., Ding, L., Mardis, E. R., Wilson, R. K., Shurtleff, S., Laurence, V., Michon, J., Marec-Bérard, P., Gut, I., Downing, J., Dyer, M., Zhang, J., & Delattre, O.
Venue
Cancer Discovery
Published
2014-11-01
Volume
4
Issue
11
Pages
1342-1353
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W1994568630
Cited by
565
References
6
FWCI
29.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-0622
The paper
Tirode, F., Surdez, D., Ma, X., Parker, M., Le Deley, M. C., Bahrami, A., Zhang, Z., Lapouble, E., Grossetête-Lalami, S., Rusch, M., Reynaud, S., Rio-Frio, T., Hedlund, E., Wu, G., Chen, X., Pierron, G., Oberlin, O., Zaidi, S., Lemmon, G., . . . Delattre, O. (2014). Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-0622

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.